Skip to main content

Advertisement

SpringerLink
Log in

Toxicity of treatment for neoplastic meningitis

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Neoplastic seeding of the leptomeninges often signifies limited life expectancy. Still, patients are frequently offered aggressive multimodality therapies to palliate symptoms, and, one hopes, to prolong survival. Treatment modalities directed at the central nervous system (CNS) include radiotherapy, intra-cerebrospinal fluid (CSF) chemotherapy, standard systemic chemotherapy, and systemic high-dose chemotherapy. Because many of these modalities are used in combination, it is often difficult to discern which mode is the predominant cause of either acute or delayed complications. This review summarizes the incidence, clinical manifestations, laboratory findings, and pathology related to acute and delayed toxicity of treatment. It describes complications associated with radiotherapy, the use of an intraventricular implanted device (ie, Ommaya device), adverse effects of intra-CSF chemotherapy, and neurotoxicity, either associated with high-dose chemotherapy or manifested as delayed and chronic complications of combined therapies. All CNS-directed therapies are associated with a high rate of complications. The adverse effects of therapy profoundly affect the patient’s quality of life, both at the acute phase of treatment and in late and chronic complications after therapy is completed. Intra-CSF chemotherapy is associated with a high rate of acute, reversible adverse effects that sometimes evolve into life-threatening medical conditions. Devastating delayed complications, mainly described as leukoencephalopathy, develop in more than 50% of patients who survive for extended periods and often lead to progressive loss of cognitive capacities. Careful assessment of the benefits and potential adverse reactions to a particular therapy regimen is mandated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chamberlain MC: Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 1998, 37:271–284. This review outlines the author’s experience with complications associated with intra-CSF chemotherapy based on a large series of 120 patients.

    Article  PubMed  CAS  Google Scholar 

  2. Siegal T: Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol 1998, 38:151–157. This paper reviews the current treatment modalities for leptomeningeal metastases and questions the rationale for standard use of intra-CSF therapy. Criticism is based on the high rate of adverse reactions observed with this therapy.

    Article  PubMed  CAS  Google Scholar 

  3. Bokstein F, Lossos A, Lossos IS, Siegal T: Central nervous system relapse of systemic non-Hodgkin’s lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 2002, 43:587–593.

    Article  PubMed  CAS  Google Scholar 

  4. Siegal T, Lossos A, Pfeffer MR: Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994, 44:1463–1469.

    PubMed  CAS  Google Scholar 

  5. Boogerd W, Hart AA, van der Sande JJ, Engelsman E: Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991, 67:1685–1695.

    Article  PubMed  CAS  Google Scholar 

  6. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al.: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993, 11:561–569.

    PubMed  CAS  Google Scholar 

  7. Stewart DJ, Maroun JA, Hugenholtz H, et al.: Combined intraommaya methotrexate, cytosine arabinoside, hydrocortisone and thio-TEPA for meningeal involvement by malignancies. J Neurooncol 1987, 5:315–322.

    Article  PubMed  CAS  Google Scholar 

  8. Lossos A, Siegal T: Electric shock-like sensations in 42 cancer patients: clinical characteristics and distinct etiologies. J Neurooncol 1996, 29:175–181.

    Article  PubMed  CAS  Google Scholar 

  9. Brecher ML, Berger P, Freeman AI, et al.: Computerized tomography scan findings in children with acute lymphocytic leukemia treated with three different methods of central nervous system prophylaxis. Cancer 1985, 56:2430–2433.

    Article  PubMed  CAS  Google Scholar 

  10. DeAngelis LM: Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998, 38:245–252.

    Article  PubMed  CAS  Google Scholar 

  11. Sandberg DI, Bilsky MH, Souweidane MM, et al.: Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 2000, 47:49–55. Review of a large center’s experience with intraventricular catheter placement and complication avoidance.

    Article  PubMed  CAS  Google Scholar 

  12. Shapiro WR, Posner JB, Ushio Y, et al.: Treatment of meningeal neoplasms. Cancer Treat Rep 1977, 61:733–743.

    PubMed  CAS  Google Scholar 

  13. Lishner M, Perrin RG, Feld R, et al.: Complications associated with Ommaya reservoirs in patients with cancer: the Princess Margaret Hospital experience and a review of the literature. Arch Intern Med 1990, 150:173–176.

    Article  PubMed  CAS  Google Scholar 

  14. Obbens EA, Leavens ME, Beal JW, Lee YY: Ommaya reservoirs in 387 cancer patients: a 15-year experience. Neurology 1985, 35:1274–1278.

    PubMed  CAS  Google Scholar 

  15. de Waal R, Algra PR, Heimans JJ, et al.: Methotrexate induced brain necrosis and severe leukoencephalopathy due to disconnection of an Ommaya device. J Neurooncol 1993, 15:269–273.

    Article  PubMed  Google Scholar 

  16. Dinndorf PA, Bleyer WA: Management of infectious complications of intraventricular reservoirs in cancer patients: low incidence and successful treatment without reservoir removal. Cancer Drug Deliv 1987, 4:105–117.

    PubMed  CAS  Google Scholar 

  17. Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ: Stenotrophomonas maltophilia meningitis: report of two cases and review of the literature. J Neurosurg 1997, 87:106–108.

    PubMed  CAS  Google Scholar 

  18. Siegal T, Pfeffer MR, Steiner I: Antibiotic therapy for infected Ommaya reservoir systems. Neurosurgery 1988, 22:97–100.

    Article  PubMed  CAS  Google Scholar 

  19. Hitchins RN, Bell DR, Woods RL, Levi JA: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987, 5:1655–1662.

    PubMed  CAS  Google Scholar 

  20. Glantz MJ, Jaeckle KA, Chamberlain MC, et al.: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999, 5:3394–3402. A randomized, open-label study that compares intra-CSF chemotherapy with either methotrexate or a slow-release liposomal formulation of cytarabine in LM secondary to solid tumors. Only acute complications associated with intra-CSF therapy were evaluated.

    PubMed  CAS  Google Scholar 

  21. GlantzMJ, LaFollette S, Jaeckle KA, et al.: Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110–3116. A randomized, open-label study that compares intra-CSF therapy with two formulations of cytarabine. Careful evaluation of acute complications related to intra-CSF chemotherapy is presented, confirming the higher rate of arachnoiditis with the slow-release drug.

    PubMed  CAS  Google Scholar 

  22. Pfeffer MR, Wygoda M, Siegal T: Leptomeningeal metastases: treatment results in 98 consecutive patients. Isr J Med Sci 1988, 24:611–618.

    PubMed  CAS  Google Scholar 

  23. Fizazi K, Asselain B, Vincent-Salomon A, et al.: Meningeal carcinomatosis in patients with breast carcinoma: clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 1996, 77:1315–1323.

    Article  PubMed  CAS  Google Scholar 

  24. Bokstein F, Lossos A, Siegal T: Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 1998, 82:1756–1763. This study compares the outcomes of two prospective treatment protocols that were identical in their use of radiotherapy and systemic chemotherapy and varied only in their inclusion or exclusion of intra-CSF chemotherapy. The results suggest that intra-CSF chemotherapy is a major factor in treatment-related complications. The exclusion of intra-CSF chemotherapy had no effect on treatment outcome, but it significantly reduced the rate of early and delayed complications.

    Article  PubMed  CAS  Google Scholar 

  25. Jaeckle KA, Phuphanich S, Bent MJ, et al.: Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001, 84:157–163.

    Article  PubMed  CAS  Google Scholar 

  26. Watterson J, Toogood I, Nieder M, et al.: Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 1994, 74:3034–3041.

    Article  PubMed  CAS  Google Scholar 

  27. Dunton SF, Nitschke R, Spruce WE, et al.: Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside: a Pediatric Oncology Group study. Cancer 1986, 57:1083–1088.

    Article  PubMed  CAS  Google Scholar 

  28. Bellon JR, Smith AS, Cohen ML: Ascending cord necrosis: complication of intrathecal chemotherapy with radiologicpathologic correlation. Clin Pediatr (Phila) 1995, 34:506–509.

    Article  CAS  Google Scholar 

  29. McLean DR, Clink HM, Ernst P, et al.: Myelopathy after intrathecal chemotherapy: a case report with unique magnetic resonance imaging changes. Cancer 1994, 73:3037–3040.

    Article  PubMed  CAS  Google Scholar 

  30. Bokstein F, Gomori JM, Lossos A, et al.: Neuroimaging features of subacute myelopathy induced by intra-ventricular therapy with Ara-C. Neuro-Oncology 2000, 2(Suppl 1):s12.

    Google Scholar 

  31. Eden OB, Goldie W, Wood T, Etcubanas E: Seizures following intrathecal cytosine arabinoside in young children with acute lymphoblastic leukemia. Cancer 1978, 42:53–58.

    Article  PubMed  CAS  Google Scholar 

  32. Resar LM, Phillips PC, Kastan MB, et al.: Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1993, 71:117–123.

    Article  PubMed  CAS  Google Scholar 

  33. Tetef ML, Margolin KA, Doroshow JH, et al.: Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 2000, 46:19–26.

    Article  PubMed  CAS  Google Scholar 

  34. Glantz MJ, Cole BF, Recht L, et al.: High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol 1998, 16:1561–1567. A study that further evaluates the dilemma over whether intra-CSF chemotherapy is required to achieve high drug concentrations in the subarachnoid compartment.

    PubMed  CAS  Google Scholar 

  35. Yeh KH, Cheng AL, Tien HF: Primary T cell leptomeningeal lymphoma: successful treatment with systemic chemotherapy. Oncology 1995, 52:501–504.

    Article  PubMed  CAS  Google Scholar 

  36. Morra E, Lazzarino M, Inverardi D, et al.: Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. J Clin Oncol 1986, 4:1207–1211.

    PubMed  CAS  Google Scholar 

  37. Morra E, Lazzarino M, Brusamolino E, et al.: The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia: clinical results in 46 patients. Cancer 1993, 72:439–445.

    Article  PubMed  CAS  Google Scholar 

  38. Siegal T, Zylber-Katz E: Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin Pharmacokinet 2002, 41:171–186. Evaluation of the strategies used to increase drug delivery to the CNS in view of current knowledge of drug pharmacokinetics and their relevance to clinical studies.

    Article  PubMed  CAS  Google Scholar 

  39. Martino RL, Benson AB III, Merritt JA, et al.: Transient neurologic dysfunction following moderate-dose methotrexate for undifferentiated lymphoma. Cancer 1984, 54:2003–2005.

    Article  PubMed  CAS  Google Scholar 

  40. Walker RW, Allen JC, Rosen G, Caparros B: Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986, 4:1845–1850.

    PubMed  CAS  Google Scholar 

  41. Yap HY, Blumenschein GR, Yap BS, et al.: High-dose methotrexate for advanced breast cancer. Cancer Treat Rep 1979, 63:757–761.

    PubMed  CAS  Google Scholar 

  42. Barnett MJ, Richards MA, Ganesan TS, et al.: Central nervous system toxicity of high-dose cytosine arabinoside. Semin Oncol 1985, 12(Suppl 3):227–232.

    PubMed  CAS  Google Scholar 

  43. Benger A, Browman GP, Walker IR, Preisler HD: Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a leukemia Intergroup report. Cancer Treat Rep 1985, 69:240–241.

    PubMed  CAS  Google Scholar 

  44. Hwang TL, Yung WK, Lee YY, et al.: High dose Ara-C related leukoencephalopathy. J Neurooncol 1986, 3:335–339.

    Article  PubMed  CAS  Google Scholar 

  45. Dworkin LA, Goldman RD, Zivin LS, Fuchs PC: Cerebellar toxicity following high-dose cytosine arabinoside. J Clin Oncol 1985, 3:613–616.

    PubMed  CAS  Google Scholar 

  46. Herzig RH, Hines JD, Herzig GP, et al.: Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987, 5:927–932.

    PubMed  CAS  Google Scholar 

  47. Hoffman DL, Howard JR Jr, Sarma R, Riggs JE: Encephalopathy, myelopathy, optic neuropathy, and anosmia associated with intravenous cytosine arabinoside. Clin Neuropharmacol 1993, 16:258–262.

    Article  PubMed  CAS  Google Scholar 

  48. Vogel H, Horoupian DS: Filamentous degeneration of neurons: a possible feature of cytosine arabinoside neurotoxicity. Cancer 1993, 71:1303–1308.

    Article  PubMed  CAS  Google Scholar 

  49. Winkelman MD, Hines JD: Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 1983, 14:520–527.

    Article  PubMed  CAS  Google Scholar 

  50. Ochs J, Mulhern R, Fairclough D, et al.: Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Clin Oncol 1991, 9:145–151.

    PubMed  CAS  Google Scholar 

  51. Peylan-Ramu N, Poplack DG, Pizzo PA, et al.: Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy. N Engl J Med 1978, 298:815–818.

    Article  PubMed  CAS  Google Scholar 

  52. Meyers CA, Yung WK: Delayed neurotoxicity of intraventricular interleukin-2: a case report. J Neurooncol 1993, 15:265–267.

    Article  PubMed  CAS  Google Scholar 

  53. Meyers CA, Obbens EA, Scheibel RS, Moser RP: Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 1991, 68:88–92.

    Article  PubMed  CAS  Google Scholar 

  54. Siegal T, Ovadia H, Yatsiv I, Abramsky O: CSF myelin basic protein levels in leptomeningeal metastases: relationship to disease activity. J Neurol Sci 1987, 78:165–173.

    Article  PubMed  CAS  Google Scholar 

  55. Gangji D, Reaman GH, Cohen SR, et al.: Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. N Engl J Med 1980, 303:19–21.

    Article  PubMed  CAS  Google Scholar 

  56. Lesnik PG, Ciesielski KT, Hart BL, et al.: Evidence for cerebellar-frontal subsystem changes in children treated with intrathecal chemotherapy for leukemia: enhanced data analysis using an effect size model. Arch Neurol 1998, 55:1561–1568. In this study detailed morphometric evaluations of the brains of survivors of childhood acute lymphoblastic leukemia were conducted together with neuropsychological assessment. The study included patients whose CNS prophylaxis consisted of intra-CSF chemotherapy without radiotherapy. Delayed structural and functional effects were found.

    Article  PubMed  CAS  Google Scholar 

  57. Ongerboer de Visser BW, Somers R, Nooyen WH, et al.: Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 1983, 33:1565–1572.

    PubMed  CAS  Google Scholar 

  58. Grant R, Naylor B, Greenberg HS, Junck L: Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 1994, 51:457–461.

    PubMed  CAS  Google Scholar 

  59. Chamberlain MC, Kormanik PA, Barba D: Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997, 87:694–699. This paper summarizes one institutional experience with complications observed in 120 consecutive patients with LM who were given combination treatment that included intraventricular chemotherapy.

    Article  PubMed  CAS  Google Scholar 

  60. Giannone L, Greco FA, Hainsworth JD: Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986, 4:68–73.

    PubMed  CAS  Google Scholar 

  61. Chamberlain MC, Kormanik PR: Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 1997, 35:55–64.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuro-Oncology Center, Hadassah Hebrew University Hospital, Ein-Kerem, PO Box 12000, 91120, Jerusalem, Israel

    Tali Siegal MD

Authors
  1. Tali Siegal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siegal, T. Toxicity of treatment for neoplastic meningitis. Curr Oncol Rep 5, 41–49 (2003). https://doi.org/10.1007/s11912-003-0085-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-003-0085-8

Keywords

Search

Navigation